Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Friday. The brokerage issued a sell rating on the stock.

Oragenics Stock Down 8.3 %

Shares of NYSE OGEN opened at $0.35 on Friday. The firm has a market cap of $1.59 million, a PE ratio of -0.04 and a beta of 0.45. Oragenics has a 12-month low of $0.35 and a 12-month high of $7.74. The company’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $1.18.

Oragenics (NYSE:OGEN) last issued its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission (SEC). 18.71% of the stock is currently owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.